68Ga-PSMA-PET/CT代谢反应对盆腔淋巴结阳性前列腺癌根治性放疗后的预后价值
本研究回顾性分析107例接受根治性放疗联合雄激素剥夺治疗(ADT)的盆腔淋巴结转移性前列腺癌患者,于治疗前后行68Ga-PSMA-PET/CT评估代谢反应。中位随访60.4个月,治疗后淋巴结完全代谢反应(CMR)与更优的5年无远处转移生存、无进展生存和前列腺癌特异性生存显著相关;淋巴结CMR和ADT≥24个月为独立预后预测因素。
要点
- 治疗后68Ga-PSMA-PET/CT显示淋巴结CMR者5年DMFS达87.3%,显著优于非CMR的42.6%。
- 原发灶CMR亦与改善的5年DMFS、PFS和PCSS相关。
- 淋巴结CMR和ADT≥24个月是多变量分析中DMFS、PFS和PCSS的独立预测因素。
核心结论
- 治疗后68Ga-PSMA-PET/CT代谢反应是盆腔淋巴结转移性前列腺癌患者长期结局的显著预测因素。
- 淋巴结完全代谢反应和延长ADT(≥24个月)是改善生存的独立预测因素。
- 支持使用68Ga-PSMA-PET/CT对盆腔淋巴结转移性前列腺癌进行治疗后反应评估。
研究设计与样本
- 回顾性研究分析2015年10月至2023年6月间治疗的107例前列腺癌伴盆腔淋巴结转移患者。
- 所有患者接受前列腺及盆腔放疗、ADT至少18个月,并完成治疗前后68Ga-PSMA-PET/CT用于分期、放疗计划和反应评估。
- 主要终点为无远处转移生存(DMFS),次要终点为无进展生存(PFS)和前列腺癌特异性生存(PCSS)。
主要发现
- 中位随访60.4个月,放疗后中位4.1个月行治疗后68Ga-PSMA-PET/CT,显示98.1%原发灶和93.5%淋巴结SUVmax下降。
- 原发灶CMR率为43.9%,淋巴结CMR率为65.4%。
- 原发灶CMR与改善的5年DMFS(81.6% vs 61.4%;P = .006)、PFS(72.2% vs 41.0%;P = .01)和PCSS(96.4% vs 84.7%;P = .04)相关。
- 淋巴结CMR与更优的5年DMFS(87.3% vs 42.6%;P < .001)、PFS(72.6% vs 25.9%;P < .001)和PCSS(97.5% vs 77.1%;P < .001)相关。
- 多变量分析中,ADT≥24个月和淋巴结CMR是DMFS、PFS和PCSS改善的独立预测因素,Gleason评分≥8与更差DMFS相关。
关键数值与推荐
- 原发灶CMR:5年DMFS 81.6% vs 61.4%(P = .006),PFS 72.2% vs 41.0%(P = .01),PCSS 96.4% vs 84.7%(P = .04)。
- 淋巴结CMR:5年DMFS 87.3% vs 42.6%(P < .001),PFS 72.6% vs 25.9%(P < .001),PCSS 97.5% vs 77.1%(P < .001)。
- ADT≥24个月和淋巴结CMR为DMFS、PFS和PCSS改善的独立预测因素;Gleason评分≥8与更差DMFS相关。
临床怎么用
- 对盆腔淋巴结转移性前列腺癌根治性放疗后患者,可考虑行68Ga-PSMA-PET/CT评估代谢反应以辅助预后判断。
- 治疗后淋巴结完全代谢反应提示长期生存预后更优,可据此加强随访或调整后续治疗策略。
- ADT持续时间≥24个月与改善生存独立相关,支持在合适患者中延长ADT疗程。
局限性
- 本研究为回顾性设计,存在选择偏倚可能。
- 单中心研究,样本量有限(107例),结论需外部验证。
- 治疗后PET/CT扫描时间窗(中位4.1个月)及CMR定义可能影响结果可比性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The purpose of this study was to evaluate the prognostic value of metabolic response assessed by Gallium-68-labeled prostate-specific membrane antigen positron emission tomography/computed tomography (68Ga-PSMA-PET/CT) in prostate cancer (PCa) patients with pelvic lymph node metastases (PLNM) undergoing definitive radiation therapy (RT) and androgen deprivation therapy (ADT). METHODS AND MATERIALS: This retrospective study analyzed 107 patients with PCa and PLNM treated between October 2015 and June 2023. All patients underwent pre- and post-treatment 68Ga-PSMA-PET/CT scans for staging, RT planning, and response assessment. Each patient received prostate and pelvic field RT, underwent ADT for at least 18 months, and had a minimum follow-up period of 24 months. The primary endpoint was distant metastasis-free survival (DMFS), whereas progression-free survival (PFS) and prostate cancer-specific survival (PCSS) were evaluated as secondary endpoints. RESULTS: Over a median follow-up of 60.4 months, post-treatment 68Ga-PSMA-PET/CT obtained at a median of 4.1 months after RT showed SUVmax reductions in 98.1% of primary tumors and 93.5% of lymph nodes, with complete metabolic response (CMR) in 43.9% of primary tumors and 65.4% of lymph nodes. Primary tumor CMR was associated with improved 5-year DMFS (81.6% vs 61.4%; P = .006), PFS (72.2% vs 41.0%; P = .01), and PCSS (96.4% vs 84.7%; P = .04). Lymph node CMR correlated with superior 5-year DMFS (87.3% vs 42.6%; P < .001), PFS (72.6% vs 25.9%; P < .001), and PCSS (97.5% vs 77.1%; P < .001). In multivariable analysis, longer ADT duration (≥24 months) and lymph node CMR were independent predictors of improved DMFS, PFS, and PCSS, whereas Gleason score ≥8 was associated with poorer DMFS. CONCLUSIONS: Metabolic response on post-treatment 68Ga-PSMA-PET/CT is a significant predictor of long-term outcomes in patients with PCa and PLNM. Lymph node CMR and prolonged ADT (≥24 months) were independent predictors of improved survival, supporting the use of 68Ga-PSMA-PET/CT for post-treatment response assessment in PCa with PLNM.
引用
- Onal C, Guler OC, Torun N, et al. Gallium-68-Labeled Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography Response in Pelvic Node-Positive Prostate Cancer After Definitive Radiation Therapy: Prognostic Implications. Int J Radiat Oncol Biol Phys. 2025. PMID: 41031987. doi:10.1016/j.ijrobp.2025.06.3858
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。